Molecular basis of pharmacological therapy in Cushing's disease

Endocrine

Volumn 46, Issue 2, 2014, Pages 181-198

  Ferone, Diego ^a   Pivonello, Claudia ^b   Vitale, Giovanni ^c,d   Zatelli, Maria Chiara ^e   Colao, Annamaria ^b   Pivonello, Rosario ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^e UNIVERSITY OF FERRARA   (Italy)

Author keywords

Adrenal; Cushing's disease; Medical therapy; Molecular; Pituitary

Indexed keywords

4 AMINOBUTYRIC ACID; AMINOGLUTETHIMIDE; BEVACIZUMAB; BROMOCRIPTINE; CABERGOLINE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CYPROHEPTADINE; DESMOPRESSIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOMIDATE; HYDROCORTISONE; KETANSERIN; KETOCONAZOLE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METERGOLINE; METYRAPONE; MIFEPRISTONE; MITOTANE; OCTREOTIDE; PASIREOTIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN TYROSINE KINASE; RETINOIC ACID; RITANSERIN; ROSIGLITAZONE; TEMOZOLOMIDE; TRILOSTANE; UNINDEXED DRUG; VALPROIC ACID; GLUCOCORTICOID RECEPTOR;

ADRENAL CORTEX FUNCTION; CORTICOSTEROID METABOLISM; CORTICOSTEROID RELEASE; CUSHING DISEASE; DRUG INDICATION; DRUG MECHANISM; HORMONAL REGULATION; HORMONE INHIBITION; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MOLECULAR DYNAMICS; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; REVIEW; STEROIDOGENESIS; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; HYPOPHYSIS; HYPOTHALAMUS; METABOLISM; PITUITARY ACTH HYPERSECRETION;

HUMANS; HYPOTHALAMUS; PITUITARY ACTH HYPERSECRETION; PITUITARY GLAND; RECEPTORS, GLUCOCORTICOID;

EID: 84902342860     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-013-0098-5     Document Type: Review

References (171)

1. R. Pivonello, M.C. De Martino, M. De Leo, G. Lombardi, A. Colao, Cushing's syndrome. Endocrinol. Metab. Clin. N. Am. 37, 135-149 (2008)
2. B.M. Biller, A.B. Grossman, P.M. Stewart, S. Melmed, X. Bertagna, J. Bertherat, M. Buchfelder, A. Colao, A.R. Hermus, L.J. Hofland, A. Klibanski, A. Lacroix, J.R. Lindsay, J. Newell-Price, L.K. Nieman, S. Petersenn, N. Sonino, G.K. Stalla, B. Swearingen, M.L. Vance, J.A. Wass, M. Boscaro, Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J. Clin. Endocrinol. Metab. 93, 2454-2462 (2008)
3. J.S. Lim, S.K. Lee, S.H. Kim, E.J. Lee, S.H. Kim, Intraoperative multiple-staged resection and tumor tissue identification using frozen sections provide the best result for the accurate localization and complete resection of tumors in Cushing's disease. Endocrine 40, 452-461 (2011)
4. A.E. Calogero, Neurotransmitter regulation of the hypothalamic corticotropin-releasing hormone neuron. Ann. N. Y. Acad. Sci. 771, 31-40 (1995)
5. R. Giordano, M. Pellegrino, A. Picu, L. Bonelli, M. Balbo, R. Berardelli, F. Lanfranco, E. Ghigo, E. Arvat, Neuroregulation of the hypothalamus- pituitary-adrenal (HPA) axis in humans: effects of GABA-, mineralocorticoid-, and GH-secretagogue-receptor modulation. Sci. World J. 6, 1-11 (2006)
6. R.W. Fuller, The involvement of serotonin in regulation of pituitary-adrenocortical function. Front. Neuroendocrinol. 13, 250-270 (1992)
7. B. Ambrosi, M. Gaggini, F. Secchi, G. Faglia, Lack of effect of antiserotoninergic and/or dopaminergic treatment in patients with pituitary-dependent Cushing's syndrome. Horm. Metab. Res. 11, 318-319 (1979)
8. F. Cavagnini, U. Raggi, P. Micossi, A. Di Landro, C. Invitti, Effect of an antiserotoninergic drug, metergoline, on the ACTH and cortisol response to insulin hypoglycemia and lysine-vasopressin in man. J. Clin. Endocrinol. Metab. 43, 306-312 (1976)
9. N. Sonino, G.A. Fava, F. Fallo, A. Franceschetto, P. Belluardo, M. Boscaro, Effect of the serotonin antagonists ritanserin and ketanserin in Cushing's disease. Pituitary 3, 55-59 (2000)
10. R. Tanakol, F. Alagöl, H. Azizlerli, O. Sandalci, T. Terzioǧlu, F. Berker, Cyproheptadine treatment in Cushing's disease. J. Endocrinol. Invest. 19, 242-247 (1996)
11. K.I. Alexandraki, A.B. Grossman, Pituitary-targeted medical therapy of Cushing's disease. Expert Opin. Investig. Drugs 17, 669-677 (2008)
12. T. Suda, F. Tozawa, T. Mouri, A. Sasaki, T. Shibasaki, H. Demura, K. Shizume, Effects of cyproheptadine, reserpine, and synthetic corticotropin-releasing factor on pituitary glands from patients with Cushing's disease. J. Clin. Endocrinol. Metab. 56, 1094-1099 (1983)
13. D.T. Krieger, L. Amorosa, F. Linick, Cyproheptadine-induced remission of Cushing's disease. N. Engl. J. Med. 293, 893-896 (1975)
14. N.G. Bowery, D.R. Hill, A.L. Hudson, G.W. Price, W.J. Turnbull, G.P. Wilson, Heterogeneity of mammalian GABA receptors, in Actions and interactions of GABA and benzodiazepine, ed. by N.G. Bowery (Raven Press, New York, 1984), pp. 81-108
15. J. Takahara, S. Yumoki, W. Yakushji, J. Yamauchi, H. Hosogi, T. Ofuji, Stimulatory effects of gamma-aminohydroxybutyric acid (GABOB) on growth hormone, prolactin and cortisol release in man. Horm. Metab. Res. 12, 31-34 (1980)
16. P.M. Plotsky, S. Otto, S. Sutton, Neurotransmitter modulation of corticotropin releasing factor secretion into the hypophysialportal circulation. Life Sci. 41, 1311-1317 (1987)
17. H.P. Koppeschaar, R.J. Croughs, J.H. Thijssen, F. Schwarz, Sodium valproate and cyproheptadine may independently induce a remission in the same patient with Cushing's disease. Acta Endocrinol. (Copenh). 104, 160-163 (1983)
18. A. Beckers, A. Stevenaert, G. Pirens, P. Flandroy, J. Sulon, G. Hennen, Cyclical Cushing's disease and its successful control under sodium valproate. J. Endocrinol. Invest. 13, 923-929 (1990)
19. A. Colao, R. Pivonello, F.S. Tripodi, F. Orio Jr, D. Ferone, G. Cerbone, C. Di Somma, B. Merola, G. Lombardi, Failure of long-term therapy with sodium valproate in Cushing's disease. J. Endocrinol. Invest. 20, 387-392 (1997)
20. S.S. Nussey, P. Price, J.S. Jenkins, A.R. Altaher, B. Gillham, M.T. Jones, The combined use of sodium valproate and metyrapone in the treatment of Cushing's syndrome. Clin. Endocrinol. (Oxf). 28, 373-380 (1988)
21. M. Mannelli, G. Cantini, G. Poli, M. Mangoni, G. Nesi, L. Canu, E. Rapizzi, E. Borgogni, T. Ercolino, V. Piccini, M. Luconi, Role of the PPAR-γ system in normal and tumoral pituitary corticotropic cells and adrenal cells. Neuroendocrinology 92(Suppl 1), 23-27 (2010)
22. A.P. Heaney, M. Fernando, W.H. Yong, S. Melmed, Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat. Med. 8, 1281-1287 (2002)
23. K. Winczyk, J. Kunert-Radek, A. Gruszka, M. Radek, H. Ławnicka, M. Pawlikowski, Effects of rosiglitazone-peroxisome proliferators-activated receptor gamma (PPARgamma) agonist on cell viability of human pituitary adenomas in vitro. Neuro. Endocrinol. Lett. 30, 107-110 (2009)
24. L. Kreutzer, I. Jeske, B. Hofmann, I. Blumcke, R. Fahlbusch, M. Buchfelder, R. Buslei, No effect of the PPAR-gamma agonist rosiglitazone on ACTH or cortisol secretion in Nelson's syndrome and Cushing's disease in vitro and in vivo. Clin. Neuropathol. 28, 430-439 (2009)
25. M. Manning, A. Misicka, A. Olma, K. Bankowski, S. Stoev, B. Chini, T. Durroux, B. Mouillac, M. Corbani, G. Guillon, Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics. J. Neuroendocrinol. 24, 609-628 (2012)
26. G. Narayen, S.N. Mandal, Vasopressin receptor antagonists and their role in clinical medicine. Indian J. Endocrinol. Metab. 16, 183-191 (2012)
27. D.E. Schteingart, Drugs in the medical treatment of Cushing's syndrome. Expert Opin. Emerg. Drugs 14, 661-671 (2009)
28. M. Páez-Pereda, D. Kovalovsky, U. Hopfner, M. Theodoropoulou, U. Pagotto, E. Uhl, M. Losa, J. Stalla, Y. Grübler, C. Missale, E. Arzt, G.K. Stalla, Retinoic acid prevents experimental Cushing syndrome. J. Clin. Invest. 108, 1123-1131 (2001)
29. D. Giacomini, M. Páez-Pereda, M. Theodoropoulou, M. Labeur, D. Refojo, J. Gerez, A. Chervin, S. Berner, M. Losa, M. Buchfelder, U. Renner, G.K. Stalla, E. Arzt, Bone morphogenetic protein-4 inhibits corticotroph tumor cells: involvement in the retinoic acid inhibitory action. Endocrinology 147, 247-256 (2006)
30. V. Castillo, D. Giacomini, M. Páez-Pereda, J. Stalla, M. Labeur, M. Theodoropoulou, F. Holsboer, A.B. Grossman, G.K. Stalla, E. Arzt, Retinoic acid as a novel medical therapy for Cushing's disease in dogs. Endocrinology 147, 4438-4444 (2006)
31. F. Pecori Giraldi, A.G. Ambrogio, M. Andrioli, F. Sanguin, I. Karamouzis, S.M. Corsello, C. Scaroni, E. Arvat, A. Pontecorvi, F. Cavagnini, Potential role for retinoic acid in patients with Cushing's disease. J. Clin. Endocrinol. Metab. 97, 3577-3583 (2012)
32. R.M. Luque, M.D. Gahete, U. Hochgeschwender, R.D. Kineman, Evidence that endogenous SST inhibits ACTH and ghrelin expression by independent pathways. Am. J. Physiol. Endocrinol. Metab. 291, E395-E403 (2006)
33. D. Cervia, D. Fehlmann, D. Hoyer, Native somatostatin sst2 and sst5 receptors functionally coupled to Gi/o-protein, but not to the serum response element in AtT-20 mouse tumour corticotrophs. Naunyn Schmiedebergs Arch. Pharmacol. 367, 387-578 (2003)
34. M.Z. Strowski, M.P. Dashkevicz, R.M. Parmar, H. Wilkinson, M. Kohler, J.M. Schaeffer, A.D. Blake, Somatostatin receptor subtypes 2 and 5 inhibit corticotropin-releasing hormone-stimulated adrenocorticotropin secretion from AtT-20 cells. Neuroendocrinology 75, 339-346 (2002)
35. S. Nielsen, S. Mellemkjaer, L.M. Rasmussen, T. Ledet, N. Olsen, M. Bojsen-Møller, J. Astrup, J. Weeke, J.O. Jørgensen, Expression of somatostatin receptors on human pituitary adenomas in vivo and ex vivo. J. Endocrinol. Invest. 24, 430-437 (2001)
36. U.I. Richardson, A. Schonbrunn, Inhibition of adrenocorticotropin secretion by somatostatin in pituitary cells in culture. Endocrinology 108, 281-290 (1981)
37. A. Ben-Shlomo, K.A. Wawrowsky, I. Proekt, N.M. Wolkenfeld, S.R. Ren, J. Taylor, M.D. Culler, S. Melmed, Somatostatin receptor type 5 modulates somatostatin receptor type 2 regulation of adrenocorticotropin secretion. J. Biol. Chem. 280, 24011-24021 (2005)
38. J. van der Hoek, M. Waaijers, P.M. van Koetsveld, D. Sprij-Mooij, R.A. Feelders, H.A. Schmid, P. Schoeffter, D. Hoyer, D. Cervia, J.E. Taylor, M.D. Culler, S.W. Lamberts, L.J. Hofland, Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. Am. J. Physiol. Endocrinol. Metab. 289, E278-E287 (2005)
39. L.J. Hofland, J. van der Hoek, R. Feelders, M.O. van Aken, P.M. van Koetsveld, M. Waaijers, D. Sprij-Mooij, C. Bruns, G. Weckbecker, W.W. de Herder, A. Beckers, S.W. Lamberts, The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur. J. Endocrinol. 152, 645-654 (2005)
40. M.C. Zatelli, D. Piccin, C. Vignali, F. Tagliati, M.R. Ambrosio, M. Bondanelli, V. Cimino, A. Bianchi, H.A. Schmid, M. Scanarini, A. Pontecorvi, L. De Marinis, G. Maira, E.C. degli Uberti, Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. Endocr. Relat. Cancer 14, 91-102 (2007)
41. A.P. Silva, P. Schoeffter, G. Weckbecker, C. Bruns, H.A. Schmid, Regulation of CRH-induced secretion of ACTH and corticosterone by SOM230 in rats. Eur. J. Endocrinol. 153, R7-R10 (2005)
42. L.A. Nolan, H.A. Schmid, A. Levy, Octreotide and the novel multi-receptor ligand somatostatin receptor agonist pasireotide (SOM230), block the adrenalectomy-induced increase in mitotic activity in male rat anterior pituitary. Endocrinology 148, 2821-2827 (2007)
43. J. van der Hoek, S.W. Lamberts, L.J. Hofland, The role of somatostatin analogs in Cushing's disease. Pituitary 7, 257-264 (2004)
44. L.J. Hofland, S.W.J. Lamberts, R.A. Feelders, Role of somatostatin receptors in normal and tumoral pituitary corticotropic cells. Neuroendocrinology 92(suppl 1), 11-16 (2010)
45. M.R. Ambrosio, M. Campo, M.C. Zatelli, S.G. Cella, G. Trasforini, A. Margutti, A.E. Rigamonti, E.E. Müller, E.C. degli Uberti, Unexpected activation of pituitary-adrenal axis in healthy young and elderly subjects during somatostatin infusion. Neuroendocrinology 68, 123-128 (1998)
46. C. Invitti, F. Pecori Giraldi, A. Dubini, M. Piolini, F. Cavagnini, Effect of Sandostatin on CRF-stimulated secretion of ACTH, beta-lipotropin and beta-endorphin. Horm. Metab. Res. 23, 233-235 (1991)
47. P.J. Stafford, P.J. Kopelman, K. Davidson, L. McLoughlin, A. White, L.H. Rees, G.M. Besser, D.H. Coy, A. Grossman, The pituitary-adrenal response to CRF-41 is unaltered by intravenous somatostatin in normal subjects. Clin. Endocrinol. (Oxf). 30, 661-666 (1989)
48. H.L. Fehm, K.H. Voigt, R. Lang, K.E. Beinert, S. Raptis, E.F. Pfeiffer, Somatostatin: a potent inhibitor of ACTH-hypersecretion in adrenal insufficiency. Klin Wochenschr. 54, 173-175 (1976)
49. G. Benker, K. Hackenberg, B. Hamburger, D. Reinwein, Effects of growth hormone release-inhibiting hormone and bromocryptine (CB 154) in states of abnormal pituitary-adrenal function. Clin. Endocrinol. (Oxf). 5, 187-190 (1976)
50. G.K. Stalla, S.J. Brockmeier, U. Renner, C. Newton, M. Buchfelder, J. Stalla, O.A. Müller, Octreotide exerts different effects in vivo and in vitro in Cushing's disease. Eur. J. Endocrinol. 130, 125-131 (1994)
51. B. Ambrosi, D. Bochicchio, C. Fadin, P. Colombo, G. Faglia, Failure of somatostatin and octreotide to acutely affect the hypothalamic- pituitary-adrenal function in patients with corticotropin hypersecretion. J. Endocrinol. Invest. 13, 257-261 (1990)
52. S.W. Lamberts, J. Zuyderwijk, F. den Holder, P. van Koetsveld, L. Hofland, Studies on the conditions determining the inhibitory effect of somatostatin on adrenocorticotropin, prolactin and thyrotropin release by cultured rat pituitary cells. Neuroendocrinology 50, 44-50 (1989)
53. J. Julesz, F. Laczi, T. Janáky, F. László, Effects of somatostatin and bromocryptine on the plasma ACTH level in bilaterally adrenalectomized patients with Cushing's disease. Endokrinologie 76, 68-72 (1980)
54. C. de Bruin, R.A. Feelders, A.M. Waaijers, P.M. van Koetsveld, D.M. Sprij-Mooij, S.W.J. Lamberts, L.J. Hofland, Differential regulation of human dopamine D2 and somatostatin receptor subtype expression by glucocorticoids in vitro. J. Mol. Endocrinol. 42, 47-56 (2009)
55. A. Saveanu, P. Jaquet, Somatostatin-dopamine ligands in the treatment of pituitary adenomas. Rev. Endocr. Metab. Disord. 10, 83-90 (2009)
56. C. de Bruin, A.M. Pereira, R.A. Feelders, J.A. Romijn, F. Roelfsema, D.M. Sprij-Mooij, M.O. van Aken, A.J. van der Lelij, W.W. de Herder, S.W. Lamberts, L.J. Hofland, Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas. J. Clin. Endocrinol. Metab. 94, 1118-1124 (2009)
57. T. Tateno, M. Kato, Y. Tani, K. Oyama, S. Yamada, Y. Hirata, Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas. Endocr. J. 56, 579-584 (2009)
58. D.L. Batista, X. Zhang, R. Gejman, P.J. Ansell, Y. Zhou, S.A. Johnson, B. Swearingen, E.T. Hedley-Whyte, C.A. Stratakis, A. Klibanski, The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J. Clin. Endocrinol. Metab. 91, 4482-4488 (2006)
59. E. Hubina, A.M. Nanzer, M.R. Hanson, E. Ciccarelli, M. Losa, D. Gaia, M. Papotti, M.R. Terreni, S. Khalaf, S. Jordan, S. Czirják, Z. Hanzély, G.M. Nagy, M.I. Góth, A.B. Grossman, M. Korbonits, Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours. Eur. J. Endocrinol. 155, 371-379 (2006)
60. A. Ben-Shlomo, H. Schmid, K. Wawrowsky, O. Pichurin, E. Hubina, V. Chesnokova, N.A. Liu, M. Culler, S. Melmed, Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy. J. Clin. Endocrinol. Metab. 94, 4342-4350 (2006)
61. S. Lesche, D. Lehmann, F. Nagel, H.A. Schmid, S. Schulz, Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro. J. Clin. Endocrinol. Metab. 94, 654-661 (2009)
62. M.C. Zatelli, F. Tagliati, J.E. Taylor, D. Piccin, M.D. Culler, E.C. degli Uberti, Somatostatin, but not somatostatin receptor subtypes 2 and 5 selective agonists, inhibits calcitonin secretion and gene expression in the human medullary thyroid carcinoma cell line, TT. Horm. Metab. Res. 34, 229-233 (2002)
63. A. Colao, S. Petersenn, J. Newell-Price, J.W. Findling, F. Gu, M. Maldonado, U. Schoenherr, D. Mills, L.R. Salgado, B.M. Biller, Pasireotide B2305 Study Group, A 12-month phase 3 study of pasireotide in Cushing's disease. N. Engl. J. Med. 366, 914-924 (2012)
64. R.A. Feelders, C. de Bruin, A.M. Pereira, J.A. Romijn, R.T. Netea-Maier, A.R. Hermus, P.M. Zelissen, F.H. de Jong, A.J. van der Lely, W.W. de Herder, L.J. Hofland, S.W.J. Lamberts, Stepwise medical treatment of Cushing's disease with pasireotide mono- or combination therapy with cabergoline and lowdose ketoconazole. N. Engl. J. Med. 362, 1846-1848 (2010)
65. R. Pivonello, D. Ferone, G. Lombardi, A. Colao, S.W. Lamberts, L.J. Hofland, Novel insights in dopamine receptor physiology. Eur. J. Endocrinol. 156(Suppl 1), S13-S21 (2007)
66. M. Boschetti, F. Gatto, M. Arvigo, D. Esposito, A. Rebora, M. Talco, M. Albertelli, E. Nazzari, U. Goglia, F. Minuto, D. Ferone, Role of dopamine receptors in normal and tumoral pituitary corticotropic cells and adrenal cells. Neuroendocrinology 92(Suppl 1), 17-22 (2010)
67. A. Saiardi, E. Borrelli, Absence of dopaminergic control on melanotrophs leads to Cushing's-like syndrome in mice. Mol. Endocrinol. 12, 1133-1139 (1998)
68. D. Ferone, R. Pivonello, E. Resmini, M. Boschetti, A. Rebora, M. Albertelli, V. Albanese, A. Colao, M.D. Culler, F. Minuto, Preclinical and clinical experiences with the role of dopamine receptors in the treatment of pituitary adenomas. Eur. J. Endocrinol. 156(Suppl 1), S37-S43 (2007)
69. D. Ferone, F. Gatto, M. Arvigo, E. Resmini, M. Boschetti, C. Teti, D. Esposito, F. Minuto, The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology. J. Mol. Endocrinol. 42, 361-370 (2009)
70. W.E. Farrell, A.J. Clark, M.F. Stewart, S.R. Crosby, A. White, Bromocriptine inhibits pro-opiomelanocortin mRNA and ACTH precursor secretion in small cell lung cancer cell lines. J Clin Invest. 90, 705-710 (1992)
71. D. Yin, S. Kondo, J. Takeuchi, T. Morimura, Induction of apoptosis in murine ACTH-secreting pituitary adenoma cells by bromocriptine. FEBS Lett. 339, 73-75 (1994)
72. R. Pivonello, D. Ferone, W.W. de Herder, J.M. Kros, M.L. De Caro, M. Arvigo, L. Annunziato, G. Lombardi, A. Colao, L.J. Hofland, S.W. Lamberts, Dopamine receptor expression and function in corticotroph pituitary tumors. J. Clin. Endocrinol. Metab. 89, 2452-2462 (2004)
73. M. Rocheville, D.C. Lange, U. Kumar, S.C. Patel, R.C. Patel, Y.C. Patel, Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 288, 154-157 (2000)
74. D. Ferone, A. Saveanu, M.D. Culler, M. Arvigo, A. Rebora, F. Gatto, F. Minuto, P. Jaquet, Novel chimeric somatostatin analogs: facts and perspectives. Eur. J. Endocrinol. 156(Suppl 1), S23-S28 (2007)
75. A. Saveanu, G. Gunz, S. Guillen, H. Dufour, M.D. Culler, P. Jaquet, Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas. Neuroendocrinology 83, 258-263 (2006)
76. D. Ferone, M. Arvigo, C. Semino, P. Jaquet, A. Saveanu, J.E. Taylor, J.P. Moreau, M.D. Culler, M. Albertelli, F. Minuto, A. Barreca, Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin-dopamine molecules on cell proliferation. Am. J. Physiol. Endocrinol. Metab. 289, E1044-E1050 (2005)
77. C. De Bruin, R.A. Feelders, S.W. Lamberts, L.J. Hofland, Somatostatin and dopamine receptors as targets for medical treatment of Cushing's syndrome. Rev. Endocr. Metab. Disord. 10, 91-102 (2009)
78. M. Barbot, N. Albiger, F. Ceccato, M. Zilio, A.C. Frigo, L. Denaro, F. Mantero, C. Scaroni, Combination therapy for CushingGúøs disease: effectiveness of two schedules of treatment. Should we start with cabergoline or ketoconazole? Pituitary (2013). doi:10.1007/s11102-013-0475-3
79. E.S. Newlands, G.R.P. Blackledge, J.A. Slack, G.J.S. Rustin, D.B. Smith, N.S.A. Stuart, C.P. Quarterman, R. Hoffman, M.F.G. Stevens, M.H. Brampton, A.C. Gibson, Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br. J. Cancer 65, 287-291 (1992)
80. S. Neidle, D.E. Thurston, Chemical approaches to the discovery and development of cancer therapies. Nat. Rev. Cancer 5, 285-296 (2005)
81. S. Lim, H. Shahinian, M.M. Maya, W. Yong, A.P. Heaney, Temozolomide: a novel treatment for pituitary carcinoma. Lancet Oncol. 7, 518-520 (2006)
82. F.J. Rodriguez, S.N. Thibodeau, R.B. Jenkins, K.V. Schowalter, B.L. Caron, B.P. O'neill, C.D. James, S. Passe, J. Slezak, C. Giannini, MGMT immunohistochemical expression and promoter methylation in human glioblastoma. Appl. Immunohistochem. Mol. Morphol. 16, 59-65 (2008)
83. S. Sharma, F. Salehi, B.W. Scheithauer, F. Rotondo, L.V. Syro, K. Kovacs, Role of MGMT in tumor development, progression, diagnosis, treatment and prognosis. Anticancer Res. 29, 3759-3768 (2009)
84. L.V. Syro, L.D. Ortiz, B.W. Scheithauer, R. Lloyd, Q. Lau, R. Gonzalez, H. Uribe, M. Cusimano, K. Kovacs, E. Horvath, Treatment of pituitary neoplasms with temozolomide: a review. Cancer 117, 454-462 (2011)
85. A. Takeshita, N. Inoshita, M. Taguchi, C. Okuda, N. Fukuhara, K. Oyama, K. Ohashi, T. Sano, Y. Takeuchi, S. Yamada, High incidence of low O(6)-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushing's disease. Eur. J. Endocrinol. 161, 553-559 (2009)
86. F. Salehi, B.W. Scheithauer, K. Kovacs, E. Horvath, L.V. Syro, S. Sharma, B. Manoranjan, M. Cusimano, O-6-methylguanine-DNA methyltransferase (MGMT) immunohistochemical expression in pituitary corticotroph adenomas. Neurosurgery 70, 491-496 (2012)
87. G. Raverot, F. Castinetti, E. Jouanneau, I. Morange, D. Figarella-Branger, H. Dufour, J. Trouillas, T. Brue, Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. Clin. Endocrinol. 76, 769-775 (2012)
88. K. Kovacs, B.W. Scheithauer, M. Lombardero, R.E. McLendon, L.V. Syro, H. Uribe, L.D. Ortiz, L.C. Penagos, MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathol. 115, 261-262 (2008)
89. S.S. Agarwala, J.M. Kirkwood, Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist 5, 144-151 (2000)
90. J. Sheehan, J. Rainey, J. Nguyen, R. Grimsdale, S. Han, Temozolomide-induced inhibition of pituitary adenoma cells. J. Neurosurg. 114, 354-358 (2011)
91. A. Spada, Growth factors and human pituitary adenomas. Eur. J. Endocrinol. 138, 255-257 (1998)
92. M. Niveiro, F.I. Aranda, G. Peiró, C. Alenda, A. Picó, Immunohistochemical analysis of tumor angiogenic factors in human pituitary adenomas. Hum. Pathol. 36, 1090-1095 (2005)
93. C.J. McCabe, K. Boelaert, L.A. Tannahill, A.P. Heaney, A.L. Stratford, J.S. Khaira, S. Hussain, M.C. Sheppard, J.A. Franklyn, N.J. Gittoes, Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors. J. Clin. Endocrinol. Metab. 87, 4238-4244 (2002)
94. L.D. Ortiz, L.V. Syro, B.W. Scheithauer, A. Ersen, H. Uribe, C.E. Fadul, F. Rotondo, E. Horvath, K. Kovacs, Anti-VEGF therapy in pituitary carcinoma. Pituitary 15, 445-449 (2012)
95. S. Ezzat, L. Zheng, H.S. Smyth, S.L. Asa, The c-erbB-2/neu proto-oncogene in human pituitary tumours. Clin. Endocrinol. (Oxf). 46, 599-606 (1997)
96. G. Kontogeorgos, L. Stefaneanu, K. Kovacs, Z. Cheng, Localization of epidermal growth factor (EGF) and epidermal growth factor receptor (EGFr) in human pituitary adenomas and nontumorous pituitaries: an immunocytochemical study. Endocr. Pathol. 7, 63-70 (1996)
97. O. Cooper, G. Vlotides, H. Fukuoka, M.I. Greene, S. Melmed, Expression and function of ErbB receptors and ligands in the pituitary. Endocr. Relat. Cancer 18, R197-R211 (2011)
98. D. Lubke, W. Saeger, D.K. Ludecke, Proliferation markers and EGF in ACTH-secreting adenomas and carcinomas of the pituitary. Endocr. Pathol. 6, 45-55 (1995)
99. P.A. van Wijk, J.W. van Neck, A. Rijnberk, R.J. Croughs, J.A. Mol, Proliferation of the murine corticotropic tumour cell line AtT20 is affected by hypophysiotrophic hormones, growth factors and glucocorticoids. Mol. Cell. Endocrinol. 111, 13-19 (1995)
100. H. Fukuoka, O. Cooper, A. Ben-Shlomo, A. Mamelak, S.G. Ren, D. Bruyette, S. Melmed, EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. J. Clin. Invest. 121, 4712-4721 (2011)
101. A. Gorshtein, H. Rubinfeld, E. Kendler, M. Theodoropoulou, V. Cerovac, G.K. Stalla, Z.R. Cohen, M. Hadani, I. Shimon, Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GHsecreting pituitary tumor cells in vitro. Endocr. Relat. Cancer 16, 1017-1027 (2009)
102. M.C. Zatelli, M. Minoia, C. Filieri, F. Tagliati, M. Buratto, M.R. Ambrosio, M. Lapparelli, M. Scanarini, E.C. degli Uberti, Effect of everolimus on cell viability in nonfunctioning pituitary adenomas. J. Clin. Endocrinol. Metab. 95, 968-976 (2010)
103. D. Dworakowska, E. Wlodek, C.A. Leontiou, S. Igreja, M. Cakir, M. Teng, N. Prodromou, M.I. Goth, S. Grozinsky-Glasberg, M. Gueorguiev, B. Kola, M. Korbonits, A.B. Grossman, Activation of RAF/MEK/ERK and PI3 K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors. Endocr. Relat. Cancer 16, 1329-1338 (2009)
104. E. Jouanneau, A. Wierinckx, F. Ducray, V. Favrel, F. Borson-Chazot, J. Honnorat, J. Trouillas, G. Raverot, New targeted therapies in pituitary carcinoma resistant to temozolomide. Pituitary 15, 37-43 (2012)
105. V. Cerovac, J. Monteserin-Garcia, H. Rubinfeld, M. Buchfelder, M. Losa, T. Florio, M. Paez-Pereda, G.K. Stalla, M. Theodoropoulou, The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells. Cancer Res. 70, 666-674 (2010)
106. K.E. O'Reilly, F. Rojo, Q.B. She, D. Solit, G.B. Mills, D. Smith, H. Lane, F.Hofmann,D.J.Hicklin,D.L.Ludwig, J. Baselga, N.Rosen, mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66, 1500-1508 (2006)
107. P.M. Stewart, S. Petersenn, Rationale for treatment and therapeutic options in Cushing's disease. Best Pract. Res. Clin. Endocrinol. Metab. 23(Suppl 1), S15-S22 (2009)
108. M. Boscaro, N. Sonino, A. Rampazzo, F. Mantero, Response of pituitary-adrenal axis to corticotrophin releasing hormone in patients with Cushing's disease before and after ketoconazole treatment. Clin. Endocrinol. (Oxf). 27, 461-467 (1987)
109. P. Loli, M.E. Berselli, M. Tagliaferri, Use of ketoconazole in the treatment of Cushing's syndrome. J. Clin. Endocrinol. Metab. 63, 1365-1371 (1986)
110. N. Sonino, The use of ketoconazole as an inhibitor of steroid production. N. Engl. J. Med. 317, 812-818 (1987)
111. R.A. Feelders, L.J. Hofland, W.W. de Herder, Medical treatment of Cushing's syndrome: adrenal-blocking drugs and ketaconazole. Neuroendocrinology 92(Suppl 1), 111-115 (2010)
112. G.K. Stalla, J. Stalla, M. Huber, J.P. Loeffler, V. Hollt, K. von Werder, O.A. Muller, Ketoconazole inhibits corticotropic cell function in vitro. Endocrinology 122, 618-623 (1988)
113. A. Angeli, R. Frairia, Ketoconazole therapy in Cushing's disease. Lancet 1, 821 (1985)
114. M. Boscaro, N. Sonino, A. Rampazzo, F. Mantero, Response of pituitary-adrenal axis to corticotrophin releasing hormone in patients with Cushing's disease before and after ketoconazole treatment. Clin. Endocrinol. (Oxf). 27, 461-467 (1987)
115. P. Loli, M.E. Berselli, M. Tagliaferri, Use of ketoconazole in the treatment of Cushing's syndrome. J. Clin. Endocrinol. Metab. 63, 1365-1371 (1986)
116. D. Engelhardt, M.M. Weber, Therapy of Cushing's syndrome with steroid biosynthesis inhibitors. J. Steroid Biochem. Mol. Biol. 49, 261-267 (1994)
117. T.A. Miettinen, Cholesterol metabolism during ketoconazole treatment in man. J. Lipid Res. 29, 43-51 (1988)
118. M.I. Dushkin, N.K. Zenkov, E.B. Menshikova, E.N. Pivovarova, G. Lyubimov, N.N. Volsky, Ketoconazole inhibits oxidative modification of low density lipoprotein. Atherosclerosis 114, 9-18 (1995)
119. X. Bertagna, L. Guignat, L. Groussin, J. Bertherat, Cushing's disease. Best Pract. Res. Clin. Endocrinol. Metab. 23, 607-623 (2009)
120. C.N. Dang, O. Trainer, Pharmacological management of Cushing's syndrome: an update. Arq. Bras. Endocrinol. Metabol. 51, 1339-1348 (2007)
121. B.A. Gross, S.A. Mindea, A.J. Pick, J.P. Chandler, H.H. Batjer, Medical management of Cushing disease. Neurosurg. Focus 23, E10 (2007)
122. J.A. Verhelst, P.J. Trainer, T.A. Howlett, L. Perry, L.H. Rees, A.B. Grossman, J.A. Wass, G.M. Besser, Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. Clin. Endocrinol. (Oxf). 35, 169-178 (1991)
123. T. Mancini, T. Porcelli, A. Giustina, Treatment of Cushing disease: overview and recent findings. Ther. Clin. Risk Manag. 6, 505-516 (2010)
124. L.K. Nieman, Medical therapy of Cushing's disease. Pituitary 5, 77-82 (2002)
125. M. Terzolo, A. Angeli, M. Fassnacht, F. Daffara, L. Tauchmanova, P.A. Conton, R. Rossetto, L. Buci, P. Sperone, E. Grossrubatscher, G. Reimondo, E. Bollito, M. Papotti, W. Saeger, S. Hahner, A.C. Koschker, E. Arvat, B. Ambrosi, P. Loli, G. Lombardi, M. Mannelli, P. Bruzzi, F. Mantero, B. Allolio, L. Dogliotti, A. Berruti, Adjuvant mitotane treatment for adrenocortical carcinoma. N. Engl. J. Med. 356, 2372-2380 (2007)
126. E. Gentilin, F. Tagliati, M. Terzolo, M. Zoli, M. Lapparelli, M. Minoia, M.R. Ambrosio, E.C. degli Uberti, M.C. Zatelli, Mitotane reduces human and mouse ACTH-secreting pituitary cells viability and function. J. Endocrinol. 218, 275-285 (2013)
127. M.C. Zatelli, E. Gentilin, F. Daffara, F. Tagliati, G. Reimondo, G. Carandina, M.R. Ambrosio, M. Terzolo, E.C. degli Uberti, Therapeutic concentrations of mitotane (o,p0-DDD) inhibit thyrotroph cell viability and TSH expression and secretion in a mouse cell line model. Endocrinology 151, 2453-2461 (2010)
128. J.P. Luton, J.A. Mahoudeau, P. Bouchard, P. Thieblot, M. Hautecouverture, D. Simon, M.H. Laudat, Y. Touitou, H. Bricaire, Treatment of Cushing's disease by o,p0DDD. Survey of 62 cases. N. Engl. J. Med. 300, 459-464 (1979)
129. D.E. Schteingart, H.S. Tsao, C.I. Taylor, A. McKenzie, R. Victoria, B.A. Therrien, Sustained remission of Cushing's disease with mitotane and pituitary irradiation. Ann. Intern. Med. 92, 613-619 (1980)
130. D. LaSala, Y. Shibanaka, A.Y. Jeng, Coexpression of CYP11B2 or CYP11B1 with adrenodoxin and adrenodoxin reductase for assessing the potency and selectivity of aldosterone synthase inhibitors. Anal. Biochem. 394, 56-61 (2009)
131. L. Amar, M. Azizi, J. Menard, S. Peyrard, C. Watson, P.F. Plouin, Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism. Hypertension 56, 831-838 (2010)
132. D.A. Calhoun, W.B. White, H. Krum, W. Guo, G. Bermann, A. Trapani, M.P. Lefkowitz, J. Menard, Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. Circulation 124, 1945-1955 (2011)
133. N.A. Tritos, B.M. Biller, Advances in medical therapies for Cushing's syndrome. Discov. Med. 13, 171-179 (2011)
134. X. Bertagna, R. Pivonello, M. Fleseriu, J. Zhang, P. Robinson, A. Taylor, C. Watson, M. Maldonado, A. Hamraian, M. Boscaro, Patients with Cushing's disease achieve normal urinary cortisol with LCI699, a potent 11B-hydroxylase inhibitor: preliminary results from a multicenter, proof-of-concept study, in 15th International and 14th European Congress of Endocrinology (ICE/ECE 2012), Florence, Italy (abstract OC1.2) (2012)
135. P. Dewis, D.C. Anderson, D.E. Bu'lock, R. Earnshaw, W.F. Kelly, Experience with trilostane in the treatment of Cushing's syndrome. Clin. Endocrinol. (Oxf). 18, 533-540 (1983)
136. P. Komanicky, R.F. Spark, J.C. Melby, Treatment of Cushing's syndrome with trilostane (WIN 24,540), an inhibitor of adrenal steroid biosynthesis. J. Clin. Endocrinol. Metab. 47, 1042-1051 (1978)
137. S. Hahner, A. Stürmer, M. Fassnacht, R.W. Hartmann, K. Schewe, S. Cochran, M. Zink, A. Schirbel, B. Allolio, Etomidate unmasks intraadrenal regulation of steroidogenesis and proliferation in adrenal cortical cell lines. Horm. Metab. Res. 42, 528-534 (2010)
138. N. Mettauer, J. Brierley, A novel use of etomidate for intentional adrenal suppression to control severe hypercortisolemia in childhood. Pediatr. Crit. Care Med. 10, e37-e40 (2009)
139. P. Kamenicky, C. Droumaguet, S. Salenave, A. Blanchard, C. Jublanc, J.F. Gautier, S. Brailly-Tabard, S. Leboulleux, M. Schlumberger, E. Baudin, P. Chanson, J. Young, Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome. J. Clin. Endocrinol. Metab. 96, 2796-2804 (2011)
140. S. Johanssen, B. Allolio, Mifepristone (RU 486) in Cushing's syndrome. Eur. J. Endocrinol. 157, 561-569 (2007)
141. M.C. Lebeau, E.E. Baulieu, Steroid antagonists and receptor-associated proteins. Hum. Reprod. 9, 437-444 (1994)
142. C.M. Bamberger, G.P. Chrousos, The glucocorticoid receptor and RU 486 in man. Ann. N. Y. Acad. Sci. 761, 296-310 (1995)
143. M.D. Heitzer, I.M. Wolf, E.R. Sanchez, S.F. Witchel, D.B. DeFranco, Glucocorticoid receptor physiology. Rev. Endocr. Metab. Disord. 8, 321-330 (2007)
144. H.F. Yang-Yen, J.C. Chambard, Y.L. Sun, T. Smeal, T.J. Schmidt, J. Drouin, M. Karin, Transcriptional interference between c-Jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction. Cell 62, 1205-1215 (1990)
145. C.M. Jewell, J.C. Webster, K.L. Burnstein, M. Sar, J.E. Bodwell, J.A. Cidlowski, Immunocytochemical analysis of hormone mediated nuclear translocation of wild type and mutant glucocorticoid receptors. J. Steroid Biochem. Mol. Biol. 55, 135-146 (1995)
146. B.W. Peeters, G.S. Ruigt, M. Craighead, P. Kitchener, Differential effects of the new glucocorticoid receptor antagonist ORG 34517 and RU486 (mifepristone) on glucocorticoid receptor nuclear translocation in the AtT20 cell line. Ann. N. Y. Acad. Sci. 1148, 536-541 (2008)
147. F. Spiga, D.M. Knight, S.K. Droste, B. Conway-Campbell, Y. Kershaw, C.P. MacSweeney, F.J. Thomson, M. Craighead, B.W. Peeters, S.L. Lightman, Differential effect of glucocorticoid receptor antagonists on glucocorticoid receptor nuclear translocation and DNA binding. J. Psychopharmacol. 25, 211-221 (2011)
148. R. Sitruk-Ware, I.M. Spitz, Pharmacological properties of mifepristone: toxicology and safety in animal and human studies. Contraception 68, 409-420 (2003)
149. X. Bertagna, C. Bertagna, M.H. Laudat, J.M. Husson, F. Girard, J.P. Luton, Pituitary-adrenal response to the antiglucocorticoid action of RU 486 in Cushing's syndrome. J. Clin. Endocrinol. Metab. 63, 639-643 (1986)
150. J.W. Chu, D.F. Matthias, J. Belanoff, A. Schatzberg, A.R. Hoffman, D. Feldman, Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486). J. Clin. Endocrinol. Metab. 86, 3568-3573 (2001)
151. A.M. Isidori, G.A. Kaltsas, C. Pozza, V. Frajese, J. Newell-Price, R.H. Reznek, P.J. Jenkins, J.P. Monson, A.B. Grossman, G.M. Besser, The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up. J. Clin. Endocrinol. Metab. 91, 371-377 (2006)
152. F. Castinetti, M. Fassnacht, S. Johanssen, M. Terzolo, P. Bouchard, P. Chanson, C. Do Cao, I. Morange, A. Pico, S. Ouzounian, J. Young, S. Hahner, T. Brue, B. Allolio, B. Conte-Devolx, Merits and pitfalls of mifepristone in Cushing's syndrome. Eur. J. Endocrinol. 160, 1003-1010 (2009)
153. F. Castinetti, B. Conte-Devolx, T. Brue, Medical treatment of Cushing's syndrome: glucocorticoid receptor antagonists and mifepristone. Neuroendocrinology 92(Suppl 1), 125-130 (2010)
154. M. Fleseriu, B.M. Biller, J.W. Findling, M.E. Molitch, D.E. Schteingart, C. Gross, Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J. Clin. Endocrinol. Metab. 97, 2039-2049 (2012)
155. P.M. Stewart, B.R. Walker, G. Holder, D. O'Halloran, C.H. Shackleton, 11 beta-Hydroxysteroid dehydrogenase activity in Cushing's syndrome: explaining the mineralocorticoid excess state of the ectopic adrenocorticotropin syndrome. J. Clin. Endocrinol. Metab. 80, 3617-3620 (1995)
156. S.H. van Uum, J.W. Lenders, A.R. Hermus, Cortisol, 11beta-hydroxysteroid dehydrogenases, and hypertension. Semin. Vasc. Med. 4, 121-128 (2004)
157. J.D. Carmichael, M. Fleseriu, Mifepristone: is there a place in the treatment of Cushing's disease? Endocrine 44, 20-32 (2013)
158. G.A. Kaltsas, P. Nomikos, G. Kontogeorgos, M. Buchfelder, A.B. Grossman, Clinical review: diagnosis and management of pituitary carcinomas. J. Clin. Endocrinol. Metab. 90, 3089-3099 (2005)
159. B.T. Ragel, W.T. Couldwell, Pituitary carcinoma: a review of the literature. Neurosurg. Focus 16, 1-9 (2004)
160. R.E. Landman, M. Horwith, R.E. Peterson, A.G. Khandji, S.L. Wardlaw, Long-term survival with ACTH-secreting carcinoma of the pituitary: a case report and review of the literature. J. Clin. Endocrinol. Metab. 87, 3084-3089 (2002)
161. G.A. Kaltsas, J.J. Mukherjee, The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors. J. Clin. Endocrinol. Metab. 83, 4233-4238 (1998)
162. A.A. van der Klaauw, T. Kienitz, C.J. Strasburger, J.W. Smit, J.A. Romijn, Malignant pituitary corticotroph adenomas: report of two cases and a comprehensive review of the literature. Pituitary 12, 57-69 (2009)
163. K. Cukier, R. Tewari, F. Kurth, H.A. Schmid, C. Lai, D.J. Torpy, Significant response to pasireotide (SOM230) in the treatment of a patient with persistent, refractory Cushing's disease. Clin. Endocrinol. (Oxf). 71, 305-307 (2009)
164. H. Bode, M. Seiz, A. Lammert, M.A. Brockmann, W. Back, H.P. Hammes, C. Thomé, SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases. Exp. Clin. Endocrinol. Diabetes 118, 760-763 (2010)
165. G. Raverot, N. Sturm, F. de Fraipont, M. Muller, S. Salenave, P. Caron, O. Chabre, P. Chanson, C. Cortet-Rudelli, R. Assaker, H. Dufour, S. Gaillard, P. François, E. Jouanneau, J.G. Passagia, M. Bernier, A. Cornélius, D. Figarella-Branger, J. Trouillas, F. Borson-Chazot, T. Brue, Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J. Clin. Endocrinol. Metab. 95, 4592-4599 (2010)
166. C.E. Fadul, A.L. Kominsky, L.P. Meyer, L.S. Kingman, W.B. Kinlaw, C.H. Rhodes, C.J. Eskey, N.E. Simmons, Long-term response of pituitary carcinoma to temozolamide. Report of two cases. J. Neurosurg. 105, 621-626 (2006)
167. C. Hagen, H.D. Schroder, S. Hansen, C. Hagen, M. Andersen, Temozolamide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. Eur. J. Endocrinol. 161, 631-637 (2009)
168. A.I. McCormack, K.L. McDonald, A.J. Gill, S.J. Clark, M.G. Burt, K.A. Campbell, W.J. Braund, N.S. Little, R.J. Cook, A.B. Grossman, B.G. Robinson, R.J. Clifton-Bligh, Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin. Endocrinol. 71, 226-233 (2009)
169. M. Thearle, P. Freda, J. Bruce, S. Isaacson, Y. Lee, R. Fine, Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumor. Pituitary 14, 418-424 (2011)
170. M. Basina, H. Liu, A.R. Hoffman, D. Feldman, Successful long-term treatment of Cushing disease with mifepristone (RU486). Endocr. Pract. 18, e114-e120 (2012)
171. L.F. Chan, M. Vaidya, B. Westphal, J. Allgrove, L. Martin, F. Afshar, P.C. Hindmarsh, M.O. Savage, A.B. Grossman, H.L. Storr, Use of intravenous etomidate to control acute psychosis induced by the hypercortisolaemia in severe paediatric Cushing's disease. Horm. Res. Paediatr. 75, 441-446 (2011)